Japan approves Novocure’s Optune brain cancer treatment

Novocure (NSDQ:NVCR) said today that the Japanese Ministry of Health, Labor and Welfare has approved its tumor treating fields delivery system, Optune, for adult patients with supra-tentorial glioblastoma following surgery and radiation therapy.

The St. Helier, N.J.-based company is expected to submit an application for public reimbursement of the device in Japan for newly diagnosed GBM.

Get the full story at our sister site, Drug Delivery Business News.

The post Japan approves Novocure’s Optune brain cancer treatment appeared first on MassDevice.

from MassDevice http://ift.tt/2hiN85z